An experimental drug from Cytokinetics failed to improve the lung function of patients with ALS compared to a placebo but CEO Robert Blum says the company still intends to move to Phase 3 clinical trial. httpsbuff.ly2E0MGGkÂ
An experimental drug from Cytokinetics failed to improve the lung function of patients with ALS compared to a placebo, but CEO Robert Blum says the company still intends to move to Phase 3 clinical trial. https://buff.ly/2E0MGGk
13:00 EDT 11 May 2019 |
STAT
More From BioPortfolio on "An experimental drug from Cytokinetics failed to improve the lung function of patients with ALS compared to a placebo, but CEO Robert Blum says the company still intends to move to Phase 3 clinical trial. https://buff.ly/2E0MGGk "